Beijing Luzhu Biotechnology Co Ltd H share 02480
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- HKD 26.80
- Day Range
- HKD 26.50–26.50
- 52-Week Range
- HKD 17.00–42.00
- Bid/Ask
- HKD 17.60 / HKD 26.50
- Market Cap
- HKD 6.95 Bil
- Volume/Avg
- 200 / 4,560
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Beijing Luzhu Biotechnology Co Ltd is a biotechnology company committed to developing innovative human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. Its clinical-stage product candidates comprise one vaccine candidate, LZ901 and two antibody injection product candidates, including K3 and K193. LZ901 is our Core Product.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 129
- Website
- http://www.luzhubiotech.com
Comparables
Valuation
|
Metric
|
02480
|
02315
|
002007
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 28.45 |
Price/Book Value | 4.77 | 4.52 | 3.09 |
Price/Sales | — | 4.94 | 6.85 |
Price/Cash Flow | — | — | 34.99 |
Price/Earnings
02480
02315
002007
Financial Strength
|
Metric
|
02480
|
02315
|
002007
|
|---|---|---|---|
Quick Ratio | 13.22 | 1.02 | 2.68 |
Current Ratio | 13.27 | 1.30 | 4.01 |
Interest Coverage | −200.71 | −5.27 | 140.38 |
Quick Ratio
02480
02315
002007
Profitability
|
Metric
|
02480
|
02315
|
002007
|
|---|---|---|---|
Return on Assets (Normalized) | −14.55% | −13.53% | — |
Return on Equity (Normalized) | −16.16% | −37.28% | — |
Return on Invested Capital (Normalized) | −16.01% | −20.22% | — |
Return on Assets
02480
02315
002007
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cqtffkmxg | Bbnxc | $567.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mrrsjkcy | Jwdvfvb | $109.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pfbxtbkd | Mwccvgs | $105.3 Bil | |
MRNA
| Moderna Inc | Svvhyrskf | Xcs | $47.0 Bil | |
ARGX
| argenx SE ADR | Csfngxzf | Zbwjl | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Ztkfxtlnc | Dlkg | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ngksrdpb | Hzlrjw | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qjxlyccxv | Twmjk | $15.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wzqwsrnxm | Jwfcq | $12.7 Bil | |
INCY
| Incyte Corp | Wtsnvzkc | Xkyzfk | $12.0 Bil |